Vestor Capital LLC Makes New $9.93 Million Investment in Boston Scientific Corporation (NYSE:BSX)

Vestor Capital LLC bought a new position in Boston Scientific Corporation (NYSE:BSX - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 98,478 shares of the medical equipment provider's stock, valued at approximately $9,934,000.

Other large investors have also added to or reduced their stakes in the company. Bank Pictet & Cie Europe AG boosted its position in shares of Boston Scientific by 40.8% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock valued at $6,529,000 after acquiring an additional 21,173 shares during the last quarter. Oppenheimer & Co. Inc. boosted its position in shares of Boston Scientific by 18.8% during the 1st quarter. Oppenheimer & Co. Inc. now owns 39,523 shares of the medical equipment provider's stock valued at $3,987,000 after acquiring an additional 6,264 shares during the last quarter. Segall Bryant & Hamill LLC bought a new stake in shares of Boston Scientific during the 1st quarter valued at about $8,234,000. Blue Trust Inc. boosted its position in shares of Boston Scientific by 13.0% during the 1st quarter. Blue Trust Inc. now owns 5,000 shares of the medical equipment provider's stock valued at $504,000 after acquiring an additional 575 shares during the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S boosted its position in shares of Boston Scientific by 109.9% during the 4th quarter. BI Asset Management Fondsmaeglerselskab A S now owns 270,107 shares of the medical equipment provider's stock valued at $24,126,000 after acquiring an additional 141,398 shares during the last quarter. Institutional investors own 89.07% of the company's stock.

Insider Transactions at Boston Scientific

In related news, EVP John Bradley Sorenson sold 4,572 shares of the company's stock in a transaction on Monday, May 5th. The stock was sold at an average price of $104.54, for a total value of $477,956.88. Following the sale, the executive vice president directly owned 18,705 shares of the company's stock, valued at $1,955,420.70. This represents a 19.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $106.97, for a total value of $5,348,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares in the company, valued at approximately $19,077,243.74. This represents a 21.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 457,144 shares of company stock valued at $47,296,288 in the last three months. Company insiders own 0.50% of the company's stock.

Analyst Ratings Changes

A number of analysts recently weighed in on BSX shares. Leerink Partnrs upgraded Boston Scientific to a "strong-buy" rating in a research report on Monday, June 16th. Leerink Partners started coverage on Boston Scientific in a research report on Monday, June 16th. They issued an "outperform" rating and a $118.00 target price for the company. Robert W. Baird boosted their target price on Boston Scientific from $115.00 to $120.00 and gave the stock an "outperform" rating in a research report on Thursday, April 24th. Erste Group Bank upgraded Boston Scientific to a "strong-buy" rating in a research report on Thursday, May 8th. Finally, Citigroup restated a "buy" rating and issued a $125.00 target price (up previously from $119.00) on shares of Boston Scientific in a research report on Thursday, May 22nd. One equities research analyst has rated the stock with a hold rating, twenty-two have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $116.04.

Boston Scientific Price Performance

Shares of BSX stock opened at $103.50 on Wednesday. The stock has a market cap of $153.12 billion, a price-to-earnings ratio of 75.55, a PEG ratio of 3.02 and a beta of 0.68. The business's fifty day moving average is $103.42 and its 200 day moving average is $101.16. Boston Scientific Corporation has a twelve month low of $71.88 and a twelve month high of $107.53. The company has a quick ratio of 0.88, a current ratio of 1.45 and a debt-to-equity ratio of 0.47.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.08. The company had revenue of $4.66 billion for the quarter, compared to analysts' expectations of $4.57 billion. Boston Scientific had a return on equity of 18.67% and a net margin of 11.58%. The firm's revenue for the quarter was up 20.9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.56 earnings per share. Research analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.